293 related articles for article (PubMed ID: 25504752)
1. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models.
Peng SB; Zhang X; Paul D; Kays LM; Gough W; Stewart J; Uhlik MT; Chen Q; Hui YH; Zamek-Gliszczynski MJ; Wijsman JA; Credille KM; Yan LZ
Mol Cancer Ther; 2015 Feb; 14(2):480-90. PubMed ID: 25504752
[TBL] [Abstract][Full Text] [Related]
2. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy.
Cho BS; Zeng Z; Mu H; Wang Z; Konoplev S; McQueen T; Protopopova M; Cortes J; Marszalek JR; Peng SB; Ma W; Davis RE; Thornton DE; Andreeff M; Konopleva M
Blood; 2015 Jul; 126(2):222-32. PubMed ID: 26031918
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies.
Peng SB; Zhang X; Paul D; Kays LM; Ye M; Vaillancourt P; Dowless M; Stancato LF; Stewart J; Uhlik MT; Long H; Chu S; Obungu VH
PLoS One; 2016; 11(3):e0150585. PubMed ID: 26954567
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of [
Peng T; Wang X; Li Z; Bi L; Gao J; Yang M; Wang Y; Yao X; Shan H; Jin H
Mol Pharm; 2021 Sep; 18(9):3638-3648. PubMed ID: 34424706
[TBL] [Abstract][Full Text] [Related]
5. [
Lau J; Kwon D; Rousseau E; Zhang Z; Zeisler J; Uribe CF; Kuo HT; Zhang C; Lin KS; Bénard F
Mol Pharm; 2019 Nov; 16(11):4688-4695. PubMed ID: 31545614
[TBL] [Abstract][Full Text] [Related]
6. Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases.
Portella L; Vitale R; De Luca S; D'Alterio C; Ieranò C; Napolitano M; Riccio A; Polimeno MN; Monfregola L; Barbieri A; Luciano A; Ciarmiello A; Arra C; Castello G; Amodeo P; Scala S
PLoS One; 2013; 8(9):e74548. PubMed ID: 24058588
[TBL] [Abstract][Full Text] [Related]
7. Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells.
Rhodes LV; Bratton MR; Zhu Y; Tilghman SL; Muir SE; Salvo VA; Tate CR; Elliott S; Nephew KP; Collins-Burow BM; Burow ME
Exp Cell Res; 2011 Nov; 317(18):2573-81. PubMed ID: 21906588
[TBL] [Abstract][Full Text] [Related]
8. A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells.
Broussas M; Boute N; Akla B; Berger S; Beau-Larvor C; Champion T; Robert A; Beck A; Haeuw JF; Goetsch L; Bailly C; Dumontet C; Matthes T; Corvaia N; Klinguer-Hamour C
Mol Cancer Ther; 2016 Aug; 15(8):1890-9. PubMed ID: 27297868
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer.
Galsky MD; Vogelzang NJ; Conkling P; Raddad E; Polzer J; Roberson S; Stille JR; Saleh M; Thornton D
Clin Cancer Res; 2014 Jul; 20(13):3581-8. PubMed ID: 24727324
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC).
Hainsworth JD; Reeves JA; Mace JR; Crane EJ; Hamid O; Stille JR; Flynt A; Roberson S; Polzer J; Arrowsmith ER
Target Oncol; 2016 Oct; 11(5):643-653. PubMed ID: 27154357
[TBL] [Abstract][Full Text] [Related]
11. Bifunctional fused polypeptide inhibits the growth and metastasis of breast cancer.
Liang AL; Qian HL; Zhang TT; Zhou N; Wang HJ; Men XT; Qi W; Zhang PP; Fu M; Liang X; Lin C; Liu YJ
Drug Des Devel Ther; 2015; 9():5671-86. PubMed ID: 26527862
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
Salgia R; Weaver RW; McCleod M; Stille JR; Yan SB; Roberson S; Polzer J; Flynt A; Raddad E; Peek VL; Wijayawardana SR; Um SL; Gross S; Connelly MC; Morano C; Repollet M; Sanders R; Baeten K; D'Haese D; Spigel DR
Invest New Drugs; 2017 Jun; 35(3):334-344. PubMed ID: 28299514
[TBL] [Abstract][Full Text] [Related]
13. A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer.
Bertolini G; Cancila V; Milione M; Lo Russo G; Fortunato O; Zaffaroni N; Tortoreto M; Centonze G; Chiodoni C; Facchinetti F; Pollaci G; Taiè G; Giovinazzo F; Moro M; Camisaschi C; De Toma A; D'Alterio C; Pastorino U; Tripodo C; Scala S; Sozzi G; Roz L
Mol Ther; 2021 Oct; 29(10):2963-2978. PubMed ID: 34023505
[TBL] [Abstract][Full Text] [Related]
14. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
Kijima T; Maulik G; Ma PC; Tibaldi EV; Turner RE; Rollins B; Sattler M; Johnson BE; Salgia R
Cancer Res; 2002 Nov; 62(21):6304-11. PubMed ID: 12414661
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of triptolide on lymph node metastasis in patients with non-Hodgkin lymphoma by regulating SDF-1/CXCR4 axis in vitro.
Zhang C; Cui GH; Liu F; Wu QL; Chen Y
Acta Pharmacol Sin; 2006 Nov; 27(11):1438-46. PubMed ID: 17049119
[TBL] [Abstract][Full Text] [Related]
16. [Effect of stromal cell-derived factor-1 and its receptor CXCR4 on liver metastasis of human colon cancer].
Ding YL; Fu QY; Tang SF; Zhang JL; Li ZY; Li ZT
Zhonghua Wai Ke Za Zhi; 2009 Feb; 47(3):210-3. PubMed ID: 19563077
[TBL] [Abstract][Full Text] [Related]
17. Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression.
Perissinotto E; Cavalloni G; Leone F; Fonsato V; Mitola S; Grignani G; Surrenti N; Sangiolo D; Bussolino F; Piacibello W; Aglietta M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):490-7. PubMed ID: 15701832
[TBL] [Abstract][Full Text] [Related]
18. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer.
Tamamura H; Hori A; Kanzaki N; Hiramatsu K; Mizumoto M; Nakashima H; Yamamoto N; Otaka A; Fujii N
FEBS Lett; 2003 Aug; 550(1-3):79-83. PubMed ID: 12935890
[TBL] [Abstract][Full Text] [Related]
19. Stromal cell-derived factor-1α and macrophage migration-inhibitory factor induce metastatic behavior in CXCR4-expressing colon cancer cells.
Shin HN; Moon HH; Ku JL
Int J Mol Med; 2012 Dec; 30(6):1537-43. PubMed ID: 23023114
[TBL] [Abstract][Full Text] [Related]
20. Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587.
Peng SB; Van Horn RD; Yin T; Brown RM; Roell WC; Obungu VH; Ruegg C; Wroblewski VJ; Raddad E; Stille JR
Oncotarget; 2017 Nov; 8(55):94619-94634. PubMed ID: 29212254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]